Merck Becomes Sole Testing Provider for FDA-Approved Gene Therapies of Genetix Biotherapeutics
Merck signs a 5-year deal as sole testing provider for Genetix Biotherapeutics’ gene therapies, delivering end-to-end testing to support safe, reliable commercialisation of advanced therapies.
One-time Gene Therapy Treatments | 08/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy